Schwarz Dygos Wheeler Investment Advisors LLC Reduces Position in Johnson & Johnson (NYSE:JNJ)

Schwarz Dygos Wheeler Investment Advisors LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 0.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,710 shares of the company’s stock after selling 106 shares during the period. Schwarz Dygos Wheeler Investment Advisors LLC’s holdings in Johnson & Johnson were worth $1,983,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at $1,339,878,000. Janus Henderson Group PLC lifted its position in Johnson & Johnson by 228.1% during the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock valued at $549,223,000 after purchasing an additional 2,356,359 shares during the period. Franklin Resources Inc. boosted its holdings in Johnson & Johnson by 11.4% in the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock valued at $2,721,355,000 after purchasing an additional 1,729,281 shares during the last quarter. Amundi grew its position in Johnson & Johnson by 16.2% during the 4th quarter. Amundi now owns 11,930,183 shares of the company’s stock worth $1,698,984,000 after purchasing an additional 1,660,458 shares during the period. Finally, Holocene Advisors LP acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at about $225,040,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.6 %

Shares of JNJ opened at $166.81 on Monday. The stock has a 50 day moving average price of $152.95 and a 200 day moving average price of $156.24. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a market capitalization of $401.61 billion, a price-to-earnings ratio of 25.08, a PEG ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.29 earnings per share. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 2.97%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Analyst Ratings Changes

JNJ has been the topic of several analyst reports. Bank of America raised their target price on Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a report on Wednesday, March 5th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Stifel Nicolaus lowered their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Wells Fargo & Company cut their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Finally, Leerink Partners lowered their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $171.33.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.